Member Info for Harrogate4

Hounddog10 ---Thanks for all your input as to how this tedious and now ongoing palaver may play out, it's very helpful. There must be quite a bit of production and other stuff that seems to be being withheld from SHs while the game goes on. Any views on this or how to deal with it?

This donkey requires serious management changes. SP more or less level (give or take) for three years now.

Equanimity ---- "I found a stock with a much better asymmetric reward-to-risk and share price depressed by the recent selling by a distressed institution,"

For those who intend to stay the course, do you care to name the stock you found?

ThePublican777 Surely the votes next week ? What day is the vote ?

Thursday 29th February 2024

**** -------"they are considering what else they are willing to release to pis so that the moment the contention of the rns that they two companies are recommending approval of the bid is unsubstantiated."

come again please

News regarding the King's cancer battle is very controlled, as is the ongoing and extended news blackout of Avacta's progress as a company, together with the present moribund Avacta share price, and I wonder if there is any connection between the two.

Would it be feasible that AVA3996 was being used to treat the King?

Indicated for Myeloma, AVA 3996 is a better treatment option that Takeda's Velcade

( Bortezomib) with its precise targeting and minimal side effects for Peripheral Neuropathy in particular. Perhaps the cognoscenti of the Oncology world are agreed that AVA 3996 at present represents the current best hope for defeating the disease.

Myeloma is "a form of cancer" which was how the King's condition was described on diagnosis, and such a diagnosis would usually be picked up via the blood sample analyses which invariably accompany any cancer diagnosis prior to treatment.

Perhaps where the King is concerned, the usual de rigueur treatment protocols ie using only approved drugs, may be circumvented so as to go with the latest and best in class clinical advice and everything is then fast tracked.

Gyles Brandreth a friend of the late Queen, tells us that he has been informed that she suffered from Myeloma in her last years. Myeloma is familial.

Hopefully, whatever treatment he is receiving will be entirely successful.

Macaumike -----the complaint address is -- aimregulation@londonstockexchange.com

the more that complain the better.

Flippineck "Please bear with us and we will reply to your email in more detail in due course.#”

I would be amazed if you heard from them again but please let us know if you do.

B2HS2L --"I stand to be corrected but I think CC has been the only official to confirm multiple cancerous organs."

Do you have a link for CC's confirmation please?

Thanks

That may be so, but in the meantime we wander endlessly in the groves of Academe.

G_G_G ----" I'll be annoyed with 16-18p but will vote for it just so the grubby Patels can't get their hands on our assets."

My thoughts entirely.

G_G_G ----Let's hope it's a Counter or more than one. Any views on when they may arrive?

My guess would be week from 19th Feb onwards.

CeeD ------- "Shanta’s website provides (albeit out of date) information regarding its nine largest shareholders."

If it's not up to date information, that's breaching the AIM Rules on transparency and the provision of Shareholder information and should be reported to AIM Regulation.

Hounddog10 --- You say "I think the Board may not be on totally steady legal ground here."

Again I agree, and it's surely a good reason to complain to AIM Regulation whether or not anything will happen. This buggering about with the share price between 3.2 and 3.3 ish is going to go on for weeks as further updates are obviously being stalled while this charade is played out. It could of course all be part of the plan ---to bore us all into submission.

Hounddog10 ---- I agree with you about the AIM rules being useless but think it's still worth a go, if only to confirm shareholders' distaste for the Patel/BOD proposals. We all know it's an attempt to buyout "on the cheap" and that's what we don't like, we feel we will be missing out on soon to arrive bigger gains. At the end of the day we have to hope someone bids more for Shanta, ---we can only live in hope.

Hounddog10 ---

Plenty here in 1/3 and 2/3 posts to report to aimregulation@londonstockexchange.com as breaches of the AIM regulations. Report them, give them something to deny, as Richard Nixon used to say.

It's called "Modern Living" ----.nothing works.

I anticipate we can now expect another 2 or three weeks of the SP oscillating in the 13.2 to 13.3 range. How will we cope with the excitement?

-----presumably come in tomorrow February 1st when CC starts officially in the role of Executive Director and Head of R & D as opposed to her role hitherto as a Non Executive Director.

As I understand it, Executive Directors do the running of the company and make business decisions and Non Executive Directors do not. The CEO of Avacta ( the top Company Manager as it were) reports to the Board of Directors of which CC will be the lead person.

CC has previous experience in this type of role given her 3 years working with Novartis ( Dec 2012 ----Dec 2015) in East Hanover, New Jersey as Executive Director and Clinical Program Leader in Oncology.

Novartis and Avacta are, of course, close to each other geographically in the same road in London W12 --Wood Lane, which may bode well for the future. We will have to wait and see.

Agree LDA , noted AVCT making rare excursion above 101 today. Has something gone wrong?